Literature DB >> 34032984

Regulation of TDP-43 phosphorylation in aging and disease.

Randall J Eck1,2, Brian C Kraemer1,2,3,4,5, Nicole F Liachko6,7.   

Abstract

Insoluble inclusions of phosphorylated TDP-43 occur in disease-affected neurons of most patients with amyotrophic lateral sclerosis (ALS) and about half of patients with frontotemporal lobar degeneration (FTLD-TDP). Phosphorylated TDP-43 potentiates a number of neurotoxic effects including reduced liquid-liquid phase separation dynamicity, changes in splicing, cytoplasmic mislocalization, and aggregation. Accumulating evidence suggests a balance of kinase and phosphatase activities control TDP-43 phosphorylation. Dysregulation of these processes may lead to an increase in phosphorylated TDP-43, ultimately contributing to neurotoxicity and neurodegeneration in disease. Here we summarize the evolving understanding of major regulators of TDP-43 phosphorylation as well as downstream consequences of their activities. Interventions restoring kinase and phosphatase balance may be a generalizable therapeutic strategy for all TDP-43 proteinopathies including ALS and FTLD-TDP.

Entities:  

Keywords:  Amyotrophic lateral sclerosis (ALS); Frontotemporal lobar degeneration (FTLD); Kinases; Phosphatases; Phosphorylation; TDP-43

Year:  2021        PMID: 34032984     DOI: 10.1007/s11357-021-00383-5

Source DB:  PubMed          Journal:  Geroscience        ISSN: 2509-2723            Impact factor:   7.713


  75 in total

1.  Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Manuela Neumann; Deepak M Sampathu; Linda K Kwong; Adam C Truax; Matthew C Micsenyi; Thomas T Chou; Jennifer Bruce; Theresa Schuck; Murray Grossman; Christopher M Clark; Leo F McCluskey; Bruce L Miller; Eliezer Masliah; Ian R Mackenzie; Howard Feldman; Wolfgang Feiden; Hans A Kretzschmar; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2006-10-06       Impact factor: 47.728

2.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Tetsuaki Arai; Masato Hasegawa; Haruhiko Akiyama; Kenji Ikeda; Takashi Nonaka; Hiroshi Mori; David Mann; Kuniaki Tsuchiya; Mari Yoshida; Yoshio Hashizume; Tatsuro Oda
Journal:  Biochem Biophys Res Commun       Date:  2006-10-30       Impact factor: 3.575

Review 3.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

Review 4.  The neuropathology of FTD associated With ALS.

Authors:  Ian R A Mackenzie
Journal:  Alzheimer Dis Assoc Disord       Date:  2007 Oct-Dec       Impact factor: 2.703

5.  Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Masato Hasegawa; Tetsuaki Arai; Takashi Nonaka; Fuyuki Kametani; Mari Yoshida; Yoshio Hashizume; Thomas G Beach; Emanuele Buratti; Francisco Baralle; Mitsuya Morita; Imaharu Nakano; Tatsuro Oda; Kuniaki Tsuchiya; Haruhiko Akiyama
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

Review 6.  Functional Significance of TDP-43 Mutations in Disease.

Authors:  Emanuele Buratti
Journal:  Adv Genet       Date:  2015-08-07       Impact factor: 1.944

7.  Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies.

Authors:  Manuela Neumann; Linda K Kwong; Edward B Lee; Elisabeth Kremmer; Andrew Flatley; Yan Xu; Mark S Forman; Dirk Troost; Hans A Kretzschmar; John Q Trojanowski; Virginia M-Y Lee
Journal:  Acta Neuropathol       Date:  2009-01-06       Impact factor: 17.088

8.  Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs.

Authors:  S H Ou; F Wu; D Harrich; L F García-Martínez; R B Gaynor
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

Review 9.  The basis of clinicopathological heterogeneity in TDP-43 proteinopathy.

Authors:  Ito Kawakami; Tetsuaki Arai; Masato Hasegawa
Journal:  Acta Neuropathol       Date:  2019-09-26       Impact factor: 17.088

10.  TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing.

Authors:  Kirsty E McAleese; Lauren Walker; Daniel Erskine; Alan J Thomas; Ian G McKeith; Johannes Attems
Journal:  Brain Pathol       Date:  2016-08-24       Impact factor: 6.508

View more
  8 in total

Review 1.  Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.

Authors:  Lindsey R Hayes; Petr Kalab
Journal:  Neurotherapeutics       Date:  2022-07-05       Impact factor: 6.088

2.  Recognition of the TDP-43 nuclear localization signal by importin α1/β.

Authors:  Steven G Doll; Hamed Meshkin; Alexander J Bryer; Fenglin Li; Ying-Hui Ko; Ravi K Lokareddy; Richard E Gillilan; Kushol Gupta; Juan R Perilla; Gino Cingolani
Journal:  Cell Rep       Date:  2022-06-28       Impact factor: 9.995

Review 3.  The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?

Authors:  Davide Bassani; Matteo Pavan; Stephanie Federico; Giampiero Spalluto; Mattia Sturlese; Stefano Moro
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

4.  A Transfer-Learning-Based Deep Convolutional Neural Network for Predicting Leukemia-Related Phosphorylation Sites from Protein Primary Sequences.

Authors:  Jian He; Yanling Wu; Xuemei Pu; Menglong Li; Yanzhi Guo
Journal:  Int J Mol Sci       Date:  2022-02-03       Impact factor: 5.923

Review 5.  Expanding the TDP-43 Proteinopathy Pathway From Neurons to Muscle: Physiological and Pathophysiological Functions.

Authors:  Lauren Versluys; Pedro Ervilha Pereira; Nika Schuermans; Boel De Paepe; Jan L De Bleecker; Elke Bogaert; Bart Dermaut
Journal:  Front Neurosci       Date:  2022-02-03       Impact factor: 4.677

6.  Distinguishing post-translational modifications in dominantly inherited frontotemporal dementias: FTLD-TDP Type A (GRN) vs Type B (C9orf72).

Authors:  Laura Cracco; Emma H Doud; Grace I Hallinan; Holly J Garringer; Max H Jacobsen; Rose M Richardson; Emanuele Buratti; Ruben Vidal; Bernardino Ghetti; Kathy L Newell
Journal:  Neuropathol Appl Neurobiol       Date:  2022-07-28       Impact factor: 6.250

Review 7.  Protein Kinase CK2 and Its Potential Role as a Therapeutic Target in Huntington's Disease.

Authors:  Angel White; Anna McGlone; Rocio Gomez-Pastor
Journal:  Biomedicines       Date:  2022-08-15

Review 8.  Nanotechnology-Based Drug Delivery Strategies to Repair the Mitochondrial Function in Neuroinflammatory and Neurodegenerative Diseases.

Authors:  Luis F González; Lorenzo E Bevilacqua; Rodrigo Naves
Journal:  Pharmaceutics       Date:  2021-12-01       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.